VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
Publication
, Conference
Antozzi, C; Guptill, J; Bril, V; Gamez, J; Meuth, SG; Blanco, JLM; Nowak, RJ; Quan, D; Sevilla, T; Szczudlik, A; Hegarty, B; Jouvin, M-H ...
Published in: Clinical and Experimental Rheumatology
2023
Duke Scholars
Published In
Clinical and Experimental Rheumatology
EISSN
1593-098X
ISSN
0392-856X
Publication Date
2023
Volume
41
Issue
2
Start / End Page
498 / 498
Related Subject Headings
- Arthritis & Rheumatology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Antozzi, C., Guptill, J., Bril, V., Gamez, J., Meuth, S. G., Blanco, J. L. M., … Arroyo, S. (2023). VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS. In Clinical and Experimental Rheumatology (Vol. 41, pp. 498–498).
Antozzi, Carlo, Jeffrey Guptill, Vera Bril, Josep Gamez, Sven G. Meuth, Jose L. M. Blanco, Richard J. Nowak, et al. “VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS.” In Clinical and Experimental Rheumatology, 41:498–498, 2023.
Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Blanco JLM, et al. VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS. In: Clinical and Experimental Rheumatology. 2023. p. 498–498.
Antozzi, Carlo, et al. “VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS.” Clinical and Experimental Rheumatology, vol. 41, no. 2, 2023, pp. 498–498.
Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Blanco JLM, Nowak RJ, Quan D, Sevilla T, Szczudlik A, Hegarty B, Jouvin M-H, Jin J, Arroyo S. VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS. Clinical and Experimental Rheumatology. 2023. p. 498–498.
Published In
Clinical and Experimental Rheumatology
EISSN
1593-098X
ISSN
0392-856X
Publication Date
2023
Volume
41
Issue
2
Start / End Page
498 / 498
Related Subject Headings
- Arthritis & Rheumatology
- 1103 Clinical Sciences